- 01FY26 revenue: $60.3m; +18%; orders $62.7m.
- 02SaaS +70%; Somfit/Nexus 360; MEG timing hit.
- 03FY27: dbl-digit rev; EBITDA growth faster; drivers: SaaS, MEG, Somfit US.
Compumedics (ASX: CMP) has delivered record shipped and invoiced revenue of approximately $60.3 million for FY26, representing an 18% increase on the previous year.
The global medical device developer also recorded FY26 sales orders of approximately $62.7m, reflecting continued demand across its sleep, neurology, magnetoencephalography (MEG), and connected platform businesses.
Growth in Somfit and Nexus 360 software-as-a-service (SaaS) recurring revenue reached approximately 70%, even with Somfit D remaining short of commercial release in the US.
Compumedics expects FY26 EBITDA to increase on the back of higher revenue, cost discipline, and recurring platform growth.
Record Revenue Delivered
Compumedics confirmed shipped and invoiced revenue for FY26 came in modestly below its April guidance range of $62m to $65m.
The variance primarily reflected timing factors including further delays to MEG shipment and invoicing caused by helium availability and pricing disruption linked to conflict in the Middle East, rather than a decline in underlying demand.
The group’s MEG capital equipment revenue contributed $9.7m in FY26 after recording no revenue in the segment in FY25, with Somfit and Nexus 360 SaaS revenue increasing to $10.2m in FY26 from $6m in FY25 and $4.3m in FY24.
Sales orders for the segment increased 58% year-on-year to $10.6m, underscoring the growing contribution of connected and annuity-style revenue streams.
Board Change and Outlook
Compumedics has advised that non-executive director Christopher Barys resigned from the board effective 30 June as the group enters its next development phase.
Chief executive officer Dr David Burton thanked Mr Barys for his contribution during a nine-month tenure that supported the group’s US growth and investor engagement objectives.
“Chris brought valuable US MedTech, commercial, and capital markets experience to the Board, and we appreciate his input and perspectives over the past nine months,” Dr Burton said.
“I remain deeply impressed by the company’s vision, optimism, and perseverance, and I look forward to following its continued global success,” Mr Barys added.
Compumedics enters FY27 targeting further double-digit revenue growth and EBITDA growth at a faster rate than revenue, supported by order book conversion, ongoing MEG activity, connected SaaS expansion, and the planned US Somfit D release.
Get the wire before the market opens.
The ASX small-cap stories that matter, filed before 9am AEST. Curated by the Small Caps desk.